Back to Browse Journals » Drug Design, Development and Therapy » Volume 6

Inhaled treprostinil: a therapeutic review

Authors Channick RN, Voswinckel R, Rubin LJ

Published Date January 2012 Volume 2012:6 Pages 19—28

DOI http://dx.doi.org/10.2147/DDDT.S19281

Received 2 March 2011, Accepted 23 September 2011, Published 24 January 2012

Richard N Channick1, Robert Voswinckel2,3, Lewis J Rubin4
1Pulmonary Hypertension Program, Massachusetts General Hospital, Boston, MA, USA; 2University of Giessen Lung Center, Dept. of Internal Medicine, Giessen; 3Max-Planck-Institute for Heart and Lung Research, Dept. of Lung Development and Remodeling, Bad Nauheim, Germany; 4University of California, San Diego, La Jolla, CA, USA

Abstract: Pulmonary arterial hypertension (PAH) is a life-threatening disease which, if untreated, leads to right ventricular failure and often death. Several effective therapies are now available for PAH, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. The prostacyclin analog treprostinil has proven efficacious when delivered by subcutaneous or intravenous infusion, and most recently by inhalation. Inhaled treprostinil has been shown to be 64%–72% bioavailable in healthy volunteers. Pilot clinical studies have elucidated the acute hemodynamic effects and relative pulmonary selectivity of this agent, as well as established target dosing in PAH and nonoperable chronic thromboembolic PAH. Likewise, chronically administered inhaled treprostinil resulted in clinical and hemodynamic improvement. Both pilot studies confirmed a satisfactory safety profile in patients with PAH. The pivotal Phase III trial, TRIUMPH-I, demonstrated the efficacy and safety of inhaled treprostinil (target dose of 54 µg four times daily) in PAH patients added to background therapies of bosentan or sildenafil, as assessed by improvements in the primary endpoint, peak six-minute walk distance (median placebo-corrected treatment effect of 20 m), as well as select secondary endpoints. Inhaled treprostinil is approved by the US Food and Drug Administration for patients with World Health Organization Group I PAH to improve exercise ability. Studies establishing effectiveness included predominately patients with New York Heart Association functional class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

Keywords: pulmonary arterial hypertension, prostacyclin, treprostinil, inhaled, nebulizer

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Natural material adsorbed onto a polymer to enhance immune function

Reinaque AP, França EL, Scherer EF, Côrtes MA, Souto FJ, Honorio-França AC

Drug Design, Development and Therapy 2012, 6:209-216

Published Date: 27 August 2012

Emerging strategies and therapies for treatment of Paget’s disease of bone

Michou L, Brown JP

Drug Design, Development and Therapy 2011, 5:225-239

Published Date: 26 April 2011

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis

Emilio Portaccio

Core Evidence 2011, 6:13-21

Published Date: 6 January 2011

Treatment of hemophilia: a review of current advances and ongoing issues

Antonio Coppola, Mirko Di Capua, Matteo Nicola Dario, et al.

Journal of Blood Medicine 2010, 1:183-195

Published Date: 30 August 2010

Review of the pharmacology and clinical studies of micafungin

Alison M Bormann, Vicki A Morrison

Drug Design, Development and Therapy 2009, 3:295-302

Published Date: 10 December 2009

Protein C preserves microcirculation in a model of neonatal septic shock

Doris Fischer, Marcel F Nold, Claudia A Nold-Petry, et al

Vascular Health and Risk Management 2009, 5:775-781

Published Date: 10 September 2009

Beyond post-marketing research and MedWatch: Long-term studies of drug risks

David B Resnik

Drug Design, Development and Therapy 2007, 1:1-5

Published Date: 4 October 2007